GLP-1 Drugmakers: Viking Therapeutics, Eli Lilly Face Clinical Trials

**Implied Volatility / Movement:** Normal

## Catalyst Analysis: GLP-1 Market Growth and Clinical Trial Milestones The pharmaceutical sector is witnessing intense competition in the GLP-1 drug market, a segment poised for substantial growth. Giants like Eli Lilly ( $LLY+WL ), which has seen its stock decline 2.25% recently, are developing key candidates. However, smaller biotechs such as Viking Therapeutics ( $VKTX+WL ) present a higher-risk, higher-reward profile as they await crucial data from ongoing clinical trials. VK2735, Viking's lead candidate, demonstrated a mean weight loss of up to 14.7% in a 13-week phase 2 study, and its upcoming phase 3 trials will be pivotal for its market potential. Investors are evaluating the outcomes of these studies to gauge future market share and potential for significant stock appreciation.

## Technical Analysis & Key Risk Watch

189.59 · R1 ## Technical Analysis & Key Risk Watch 186.65 · last ## Technical Analysis & Key Risk Watch 185.71 · S1 ## Technical Analysis & Key Risk Watch 183.45 · S2 ## Technical Analysis & Key Risk Watch 173.93.

For Eli Lilly ( $LLY+WL ), trading at $1185.71, key support levels are observed at $1183.45 (S1) and $1173.93 (S2), with resistance at $1186.65 (R1) and $1189.59 (R2). The stock's RSI14 stands at 56.8. Amgen ( AMGN ), trading at $385.16, shows support at $382.21 (S1) and $372.16 (S2), with resistance at $386.82 (R1) and $398.00 (R2). Amgen's RSI14 is 68.7. Both stocks are experiencing slight declines, as indicated by their recent percentage movements ($LLY+WL -0.52%, AMGN -0.64%). The broader healthcare sector ETF ( XLV ) is trading at $162.55, with support at $162.35 (S1) and $161.36 (S2), and resistance at $162.64 (R1) and $163.42 (R2); its RSI14 is 52.4. The focus remains on the successful completion of phase 3 trials for Viking Therapeutics' VK2735, as trial results are expected to be the primary driver of stock performance.

## Impact on Healthcare Sector The development of effective GLP-1 therapies is a significant area of innovation within the healthcare sector. Companies like Eli Lilly and Amgen are established players, but emerging biotechs like Viking Therapeutics are seeking to carve out market share. Positive clinical trial results for Viking's VK2735, particularly achieving the projected 23% to 25% mean weight loss in phase 3 trials, could lead to substantial gains for the company and signal strong potential in this therapeutic class for the broader sector. Conversely, setbacks in these trials could impact investor sentiment across the GLP-1 development landscape.